Lionel Trueb

University Hospital of Lausanne — Switzerland

Medicine · Health Sciences

20h-index1.5kcitations65works14.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Emergency and Acute Care Studies(10), Immunotherapy and Immune Responses(8), Cancer Immunotherapy and Biomarkers(6), Heart Rate Variability and Autonomic Control(6)

Publications65 total

ON03 | PROTOCOL FOR A CO‐DESIGN STUDY EXPLORING EXPERIENCES OF LYMPHOMA PATIENTS, INFORMAL CAREGIVERS, AND HEALTHCARE PROFESSIONALS WITH CAR‐T THERAPY
Hematological Oncology·2025Open Access
Association of enrichment of CD7⁺CXCR3⁺ CAR T cells in infusion products with remission in relapsed or refractory diffuse large B-cell lymphoma.
Journal of Clinical Oncology·2025
Combinatorial delivery of low-dose irradiation and immunotherapy to patients with immune-excluded tumors effectively enhances CD8 <sup>+</sup> T cell functionality
2025Open Access
Enrichment of CD7+CXCR3+ CAR T-cells in infusion products is associated with durable remission in relapsed or refractory diffuse large B-cell lymphoma
Annals of Oncology·2025· 3 citedOpen Access
Novel strategies to manage CAR-T cell toxicity
Nature Reviews Drug Discovery·2025· 33 cited
Association of CD7⁺CXCR3⁺ CAR T cells with long-term remission in R/R DLBCL
2024Open Access
Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma
Immunity·2024· 36 cited
Reflections on the opportunities and challenges of applying experience‐based co‐design (EBCD) to phase 1 clinical trials in oncology
Health Expectations·2024· 3 citedOpen Access
Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 <sup>+</sup> T-myeloid cell networks in melanoma
Science Immunology·2024· 73 citedOpen Access
Enrichment of Cd7⁺Cxcr3⁺ Car T Cells in Infusion Products is Associated with Durable Remission in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
SSRN Electronic Journal·2024· 1 citedOpen Access
Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma
2023· 8 citedOpen Access
Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma
2022· 5 citedOpen Access
Patient-reported outcomes in adoptive cell-therapy trials: mind the gap
Journal for ImmunoTherapy of Cancer·2022· 2 citedOpen Access
In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.
Journal of Clinical Oncology·2021· 1 cited
Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment
Cytotherapy·2020· 20 cited
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes
Journal for ImmunoTherapy of Cancer·2020· 6 citedOpen Access
Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
Annals of Oncology·2019· 236 citedOpen Access
[Side effects of immune checkpoint inhibitors: diagnosis and management].
PubMed·2019· 2 cited
Pain management decisions in emergency hospitals are predicted by brain activity during empathy and error monitoring
British Journal of Anaesthesia·2019· 20 citedOpen Access
Safety and Tolerability of Adoptive Cell Therapy in Cancer
Drug Safety·2019· 79 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

George Coukos(17), Urs Scherrer(11), Bertrand Yersin(11), Cláudio Sartori(10), Angela Orcurto(9), Stefan Zimmermann(8), Lana E. Kandalaft(8), Pascal Nicod(8), Pierre‐Nicolas Carron(8), Olivier Hügli(8), Olivier Michielin(7), Eleonora Ghisoni(6), Alexandre Harari(6), David Barras(5), Johanna Chiffelle(5), Isaac Crespo(5), Martina Imbimbo(5), Michal Bassani‐Sternberg(5), Denarda Dangaj Laniti(5), Blanca Navarro Rodrigo(5)